# Midsummer Capital

> Midsummer Capital is a VC fund in New York backing Biotechnology and Medical. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 2
- Last investment: Mar 2010
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/midocean-partners/
- Website: http://www.midsummercapital.com

Midsummer Capital is a VC fund in New York focused on Biotechnology and Medical. MidOcean Partners is a premier alternative asset manager that specializes in middle market private equity and alternative credit investments. Since inception, the focus of MidOcean Private Equity has been on high-quality middle market companies with attractive strategic, operational and financial growth opportunities in the consumer and businessservices sectors

## Contacts

5 contacts available for Midsummer Capital. Shizune tracks 5 team members at Midsummer Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/midsummer-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Medical | 1 | 50% |
| Biopharma | 1 | 50% |
| Health Care | 1 | 50% |
| Therapeutics | 1 | 50% |

6 industries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andrew Spring | CFO & Managing Director | 0 | — |
| Debbie Hodges | COO & Managing Director | 0 | — |
| Steve Shenfeld | President | 1 | — |
| Ted Virtue | CEO | 0 | — |
| Ted Virtue | CEO | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sevion Therapeutics | Sevion is a biopharmaceutical company which discovers, develops and acquires innovative product candidates for the treatment of cancer and immunological diseases. The Company is advancing a pipeline of proprietary and partnered product candidates that leverages its unique antibody technology platforms. The Company’s antibody pipeline is beingdeveloped from technology that allows for the discovery of innovative biologic therapies to previously inaccessible targets, such as multispanning membrane proteins and ion channels that play an important role in multiple diseases. The Company also developed the first protein nanocage system allowing delivery of nucleic acids and other payloads to target cells. | $11.5M | Post-IPO Equity | Mar 29, 2010 |  |
| CEL-SCI | CEL-SCI Corporation is a biotechnology company. CEL-SCI is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. The Company's core capabilities include: drug discovery, research, development and manufacturing of complex biological substances. | $4.4M | Post-IPO Equity | Aug 20, 2009 |  |

2 of 2 investments shown.

## Co-investors
- [Alpha Capital](https://shizune.co/investors/profile/alpha-capital) — VC Fund, 2 deals together
- Iroquois Capital — VC Fund, 2 deals together
- Whalehaven Capital Fund — VC Fund, 2 deals together
- [Defiance Capital](https://shizune.co/investors/profile/defiance-capital) — VC Fund, 1 deal together
- [Heights Capital Management](https://shizune.co/investors/profile/heights-capital-management) — VC Fund, 1 deal together
- InterGroup — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Midsummer Capital invest in?

Midsummer Capital invests primarily in Biotechnology, Medical and Biopharma startups, most often at Post-IPO Equity stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Midsummer Capital?

Public channels for Midsummer Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Midsummer Capital?

The team at Midsummer Capital includes Andrew Spring (CFO & Managing Director), Debbie Hodges (COO & Managing Director) and Steve Shenfeld (President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co